We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Jacqueline joined The Generations Study research team in 2022. Prior to joining the study, she has 14 years of experience working in the NHS in acute hospital, education, and primary care settings, ...

Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.

Lucy Dan earned her Master's degree in biological sciences from Durham University. She is a ICR/Imperial Convergence Science Centre student and will investigate novel ways to target the activities of ...

Amy McGeoch earned her Bachelor's degree in biochemistry from the University of Leeds. She plans to investigate the involvement of cyclin-dependent kinase complexes in non-canonical pathways such as ...

Image: Blood brain barrier from mouse brain tissue. Image provided by the National Cancer Institute. Diffuse midline gliomas (DMGs) are one of the most aggressive and hard-to-treat childhood cancers.

Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions. One of the body’s natural ...

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient ...

When personal trainer Gemma Seager, 45, injured her back while lifting weights, she assumed it would improve with rest. But after 10 months of pain, she was diagnosed with myeloma, a type of blood ...

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma. The goal of our laboratory is to improve the treatment and survival of ...

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for ovarian cancer by the US regulatory body the Food and Drug Administration (FDA). The approval ...